Medexus Pharmaceuticals (TSX:MDP) Short-Term Debt: C$3.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
54 GF Score
Price C$5.13
GF Value C$1.86
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Short-Term Debt?

Medexus Pharmaceuticals TSX:MDP +0.98% 54 Short-Term Debt is C$3.0 Mil as of Mar. 2026. GuruFocus rates TSX:MDP with a GF Score™ of 54/100 and a GF Value™ of C$1.86 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Medexus Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was C$3.0 Mil.

Medexus Pharmaceuticals's quarterly Short-Term Debt declined from Sep. 2025 (C$29.0 Mil) to Dec. 2025 (C$9.9 Mil) and declined from Dec. 2025 (C$9.9 Mil) to Mar. 2026 (C$3.0 Mil).

Medexus Pharmaceuticals's annual Short-Term Debt increased from Mar. 2024 (C$21.3 Mil) to Mar. 2025 (C$53.1 Mil) but then declined from Mar. 2025 (C$53.1 Mil) to Mar. 2026 (C$3.0 Mil).

Medexus Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Medexus Pharmaceuticals Short-Term Debt Related Terms

Medexus Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Short-Term Debt Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.05 58.44 21.31 53.09 3.04

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.09 29.71 28.98 9.93 3.04
TSX:MDP
54GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of C$3.0 Mil mean?
Medexus Pharmaceuticals (TSX:MDP) has a Short-Term Debt of C$3.0 Mil as of Mar. 2026.
Is Medexus Pharmaceuticals' Short-Term Debt too high?
Medexus Pharmaceuticals' current Short-Term Debt is C$3.0 Mil. Overall, Medexus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Short-Term Debt compare to ZTS and UTHR?
Medexus Pharmaceuticals' Short-Term Debt of C$3.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Medexus Pharmaceuticals's current Short-Term Debt is C$3.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.86, compared to a current price of C$5.13 — trading 175.8% above its estimated fair value. The current Short-Term Debt is C$3.0 Mil. Medexus Pharmaceuticals' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Short-Term Debt is C$3.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.13 is trading 175.8% above its estimated GF Value™ of C$1.86. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Short-Term Debt: C$3.0 Mil
  • GF Value™: C$1.86 vs. price of C$5.13 (175.8% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
54GF Score

Get the complete analysis for TSX:MDP

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.13
Price
C$1.86
GF Value